drugset
drugset / Trial / NCT02255461

Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors

NCT02255461 ↗

Phase 1 Terminated 35 enrolled Pediatric Brain Tumor Consortium National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase I trial studies the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors that have grown, come back, or not responded to treatment. Palbociclib isethionate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2014-12-08
Primary completion
2019-02-25
Completion
2019-02-25

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Palbociclib Small molecule — Oral

Indications

anaplastic astrocytoma anaplastic oligodendroglioma childhood brain stem glioma childhood cerebellar astrocytic neoplasm childhood cerebral astrocytoma childhood choroid plexus neoplasm childhood medulloblastoma ependymoblastoma giant cell glioblastoma gliomatosis cerebri gliosarcoma grade III meningioma medulloepithelioma pineoblastoma supratentorial primitive neuroectodermal tumor